The medical device giant said Q3 EPS fell 2% to 91 cents, in line with views. Sales rose 3% to $4.16 bil, slightly beating views of $4.15 bil. Sales of its implantable cardioverter defibrillators hit $655 mil, $11 mil below analyst estimates. Pacemaker sales also disappointed. Medtronic (MDT) affirmed its previous guidance for the full fiscal year of 3%-4% sales growth on a constant-currency basis and raised its EPS outlook to $3.81-$3.83, the midpoint in line with analyst expectations for $3.82. Shares fell 1.2% to 56.19.